First-time biopharma launchers face interconnected challenges, including limited capital, lengthy preparation timelines, regulatory uncertainty and greater pressure to meet commercial forecasts. This white paper examines why traditional launch approaches often fall short and outlines practical strategies for building the right capabilities at the right time. Readers will learn how earlier planning, integrated execution and a flexible partnership model can help reduce launch risk, improve capital and time efficiency, and position a product to achieve its full commercial potential. [Transforma...WP_TL_0226 | PDF]
